Doctors News Hubb
Advertisement Banner
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us
No Result
View All Result
Doctors News Hubb
No Result
View All Result
Home News

High-Risk Hodgkin Lymphoma and BV+Nivolumab After HSCT

admin by admin
March 20, 2023
in News


The following is a summary of “Brentuximab vedotin plus nivolumab after autologous haematopoietic stem-cell transplantation for adult patients with high-risk classic Hodgkin lymphoma: a multicentre, phase 2 trial” published in the January, 2023 issue of Haematology by Herrera, et al.


In high-risk relapsed or refractory classic Hodgkin lymphoma patients, consolidation with brentuximab vedotin following autologous hematopoietic stem-cell transplantation (HSCT) improves progression-free survival compared to placebo. Researchers tested brentuximab vedotin and nivolumab in high-risk recurrent or refractory classic Hodgkin lymphoma patients post-autologous HSCT. Five US sites hosted phase 2 experiments. All patients were 18 or older, had high-risk relapsed or refractory classic Hodgkin lymphoma, an ECOG performance level of 0-2, and acceptable organ and bone marrow function to be included. Participants received intravenous brentuximab vedotin (1/8 mg/kg) and nivolumab (3 mg/kg) on day 1 of each 21-day cycle for a maximum of 8 cycles starting 30-60 days following autologous HSCT.

Nivolumab dosage could not be reduced. 0.5 mg/kg of brentuximab vedotin is possible. If the consumption of one drug is stopped due to toxic effects, the other can still be taken. All patients’ primary outcome was 18-month progression-free survival. Between May 3, 2017, and July 13, 2019, 59 people were registered and treated. Patients received a median of 8 cycles of brentuximab vedotin with nivolumab after 54 days (IQR 46-58) post-autologous HSCT (8–8). 34 (58%) of 59 patients were male; 29 (49%) completed all 8 cycles of brentuximab vedotin + nivolumab; 45 (76%) completed at least one drug. Follow-up averaged 29.9 months (interquartile range, 24.6-34.8). All 59 patients had 94% (95% CI 84-98) progression-free survival after 18 months.

About 17 [29%] of 59 patients required corticosteroids due to immune-related side effects, along with neutropenia (25 [42%]) and peripheral sensory neuropathy (31 [53%]). Treatment caused no deaths. Post-autologous HSCT patients with high-risk relapsed or refractory classic Hodgkin lymphoma responded well to brentuximab vedotin and nivolumab. Combination immunotherapy for typical Hodgkin lymphoma needs further study to reduce side effects, especially in high-risk patients who need more intensive treatment to avoid relapse.

The study was funded by Myers Squibb, the Leukaemia and Lymphoma Society, the Lymphoma Research Foundation, and the National Cancer Institute of the National Institutes of Health.

Source: thelancet.com/journals/lanhae/article/PIIS2352-3026(22)00318-0/fulltext



Source link

Advertisement Banner
Previous Post

Travel nurse pay remains high as states debate payment caps

Next Post

Microsoft’s Nuance adds ChatGPT successor GPT-4 to EHR

Related Posts

News

Changes in Regional Brain Volume and Professional Fighters Cognition with TES

September 21, 2023
News

Infographic Participatory Design to Support the Care of Complex Regional Pain Syndrome

September 20, 2023
News

Correlation Between WWI and Chronic Kidney Disease

September 19, 2023
News

Community-Engaged QI For Medical Students Through Action Projects

September 18, 2023
News

Antidepressants are effective in patients with comorbid depression and medical diseases

September 17, 2023
News

#VisualAbstract: Prehospital Tranexamic Acid for Severe Trauma

September 16, 2023
Next Post

Microsoft's Nuance adds ChatGPT successor GPT-4 to EHR

Recommended

Mean Length of Preclinical Detectable Phase of Glaucoma >10 Years

10 months ago

Differences and Qualities They Share

7 months ago

Pediatric mental health a top patient safety concern of 2023: ECRI

6 months ago

Turquoise Health CEO Talks Future of Healthcare Price Transparency – The Health Care Blog

9 months ago

Implementation May Be a Science, But, Alas, Medicine Remains an Art – The Health Care Blog

5 months ago

© Doctors News Hubb All rights reserved.

Use of these names, logos, and brands does not imply endorsement unless specified. By using this site, you agree to the Privacy Policy and Terms & Conditions.

Navigate Site

  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

Newsletter Sign Up.

No Result
View All Result
  • Home
  • News
  • Healthcare
  • Public Health
  • Paramedic
  • Nursing
  • Contact Us

© 2022 Doctors News Hubb All rights reserved.